ASX-Dividend-Report-Banner

Complete Genomics Announces Commercial Partnership with Human Cell Atlas to Offer its Members Stereo-seq Spatial Transcriptomics at NextGen Omics & Spatial Biology Conference

March 26, 2025 12:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Complete Genomics Announces Commercial Partnership with Human Cell Atlas to Offer its Members Stereo-seq Spatial Transcriptomics at NextGen Omics & Spatial Biology Conference
Image source: Kalkine Media

SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, announced at the NextGen Omics & Spatial Biology Conference that it has entered a commercial partnership with Human Cell Atlas (HCA) to offer its STOmics spatial transcriptomics products to HCA members.

Human Cell Atlas (HCA), an international collaborative research consortium, is mapping all cell types in the healthy body, across time from development to adulthood. This comprehensive reference map of human cells is transforming researchers' understanding of health and disease driving major advances in healthcare and medicine worldwide.

Spatio-Temporal Enhanced Resolution Omics sequencing, or Stereo-seq, is a cutting-edge spatial transcriptomics technology at the core of all Complete Genomics spatial biology solutions that enables unmatched access to the spatial transcriptome, providing researchers with a powerful tool to understand complex biological processes at the molecular level. The technology supports diverse tissue preparations, including fresh, fixed, frozen and FFPE samples for a wide range of tissues and species including humans, animals and plants.

In the coming years, new spatial genomics technologies will be critical for accelerating progress toward HCA's goal of mapping all cell types in the human body," said John Randell, HCA Executive Director. "We are glad to welcome Complete Genomics to the HCA Commercial Discount Program to facilitate access to STOmics products for HCA researchers in North America."

The Complete Genomics' DNBSEQ™ platform is the engine that powers Stereo-seq by providing the high-throughput, high-quality sequencing necessary to capture and analyze spatial gene expression data across large tissue areas with high resolution. Stereo-seq DNB chips have spots with a diameter of 0.22 µm and a center-to-center distance of 0.5 µm which provides up to 400 spots per 100 µm2, thereby allowing whole transcriptome mapping at true single cell resolution.

"HCA members will find that Stereo-seq is uniquely positioned to elevate research that requires comprehensive spatial gene expression analysis across large tissue areas," said Rob Tarbox, VP of Product and Marketing at Complete Genomics.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput cost-effective sequencing technology development since its inception in 2005. Our products have powered over 9,400 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

About the Human Cell Atlas (HCA)

The Human Cell Atlas is an international collaborative research consortium that is mapping all cell types in the healthy body, across time from development to adulthood, and eventually to old age. Creating this comprehensive reference map of human cells is transforming our understanding of health and disease to drive major advances in healthcare and medicine worldwide.

 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.